Isodiol International Inc.. Opinions on U.S. Farm Bill; Provides Update on Canadian Assets

Opinions on U.S. Farm Bill; Provides Update on Canadian Assets

(CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the”Company” or”Isodiol”) is pleased with the signing of this 2018 Farm Bill by U.S. President Trump on December 21, 2018.  The enactment was preceded by the decisive conclusions of the U.S. House of Representatives to pass the 2018 Farm Bill by a vote of 369 to 47 on December 12, 2018, and by the Senate to pass the laws in an 87-to-13 vote on December 2, 2018. 1 
 (CSE: ISOL) (OTCQB: ISOLF) is pleased with the signing of this 2018 Farm Bill by U.S. President Trump on December 21, 2018.  The enactment was preceded by the decisive conclusions of the U.S. House of Representatives to pass the 2018 Farm Bill by a vote of 369 to 47 on December 12, 2018, and by the Senate to pass the laws in an 87-to-13 vote on December 2, 2018.1 

Type=”text”>McConnell contained language allowing hemp production for study in the 2014 farm bill, and the farm bill conference report lifts federal drug restrictions that have hampered expansion of the harvest.3 The 2018 legislation also makes hemp farmers eligible for federally subsidized crop insurance.

“The Company is very pleased with the decisions of Congress and President Trump,” stated CEO of Isodiol, Marcos Agramont.  “The Company has invested resources in the United States in anticipation of the legalization of hemp, and now we believe these investments are now being validated. We remain committed to continuing the development of hemp-derived CBD for the benefit of individuals globally. ”

The Company also wishes to announce the divesting of its Canadian assets.  The business has sold its interest in Canadian National Pharma Group Inc. in exchange for a return of capital investment of CAD$900,000, which is paid in installments over the next nine months. Over the course of this transaction, no inventory was issued to CN Pharma.   The divestiture marks a strategy shift where the company intends to make its products available in Canada through manufacturing and distribution partnerships with existing Licensed Producers in multiple jurisdictions, as opposed to via a captive Licensed Dealer in British Columbia. 

“As legislation affecting hemp, cannabis, as well as the commercialization of ingredients and products derived from those sources develop, it’s crucial for us adapt our plan from time to time to benefit from these developments and correctly allocate resources,” stated Agramont.  “We consider our divestment from self-distribution in Canada, which proved to be a slow process, will enable us to engage with third parties that could assist us in broad product supply at a quicker pace. ” 

The business also has terminated its agreement with Canopy Growth Corporation and brought the Canadian distribution rights for its Pot-O-Coffee products back in house, which will allow those products to be distributed through the Company’s Canadian manufacturing and distribution network as it develops.

The business will continue to focus resources and attention to the United States and other growing markets around the world, like the United Kingdom and Mexico, for the commercialization of consumer goods produced with CBD and other hemp-derived ingredients.

Is focused on the nutritional health benefits that derive from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.”  Is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.

April 26, 2018.

Isodiol’s expansion strategy involves the development of pharmaceutical and over-the-counter drugs and continued international expansion into Latin America, Asia, and Europe.

Released at Thu, 27 Dec 2018 12:39:42 +0000

Posted in: News

Comments are closed.